Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials (Q37406798)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

Lorenz Trümper

17

object named as

Lorenz Trümper

0 references

Hans Konrad Müller-Hermelink

11

object named as

Hans-Konrad Müller-Hermelink

0 references

Michael Pfreundschuh

15

object named as

Michael Pfreundschuh

0 references

Martin-Leo Hansmann

8

object named as

Martin-Leo Hansmann

0 references

6

object named as

Michael Hummel

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Andreas Rosenwald

10

object named as

Andreas Rosenwald

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Heinz-Wolfram Bernd

1

object named as

Heinz-Wolfram Bernd

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

2

object named as

Marita Ziepert

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Wolfram Klapper

4

object named as

Wolfram Klapper

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Hans-Heinrich Wacker

5

object named as

Hans-Heinrich Wacker

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sergio B Cogliatti

14

object named as

Sergio B Cogliatti

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

21

object named as

German High Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

author name string

Christoph Thorns

3

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Harald Stein

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

German Ott

9

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Thomas F E Barth

12

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Peter Möller

13

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Norbert Schmitz

16

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Silvia Höller

18

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Markus Löffler

19

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Alfred C Feller

20

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 November 2009

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

94

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

1569-1580

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Stromal gene signatures in large-B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

State-of-the-art therapeutics: diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

6 September 2017

Clinical and prognostic relevance of the Kiel classification of non-Hodgkin lymphomas results of a prospective multicenter study by the Kiel Lymphoma Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

14 September 2017

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

26 June 2018

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Mol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

26 June 2018

Antigen presentation by human B cells: T cell proliferation induced by Epstein Barr virus B lymphoblastoid cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

26 June 2018

Clinical significance of morphologic subdivision in diffuse large cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

26 June 2018

Ki-B5: a monoclonal antibody unrelated to CD45 recognizes normal and neoplastic human B cells in routine paraffin sections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

26 June 2018

Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 September 2018

Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2770968

2 October 2018

Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody OPD4 detects neoplastic T cells but does not distinguish between CD4 and CD8 neoplastic T cells in paraffin tissue sections

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody Ki-B3 detects a formalin resistant antigen on normal and neoplastic B cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do pathologic features predict prognosis in diffuse large B-cell lymphoma?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rational histochemistry using a new microanalytic technic

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Chemically activated glass slides for frozen sections and their use in autoantibody diagnosis]

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical relevance of immunologic phenotype in diffuse large cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunologic phenotype in 30 patients with diffuse large-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://pubmed.ncbi.nlm.nih.gov/19880780

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2009.008862

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37406798&oldid=2164541930"